Research and Development
VLP Biotech currently has active programs addressing vaccine needs for malaria, anthrax, MRSA and chronic HBV. Preliminary studies are also being performed in other areas of need.
VLP Biotech is seeking partners for the above 4 vaccine candidates and/or collaborators in the design of hybrid-VLPs carrying targeted epitopes of the collaborator's choice. Optimally, B and CD4+ T cell epitopes of 6-60 amino acids, regardless of secondary structure, are ideal candidates for insertion hybrid-VLPs.
For further information contact Dr. David Whitacre at
Images courtesy of Princeton University & National Center for Biotechnology Information, U.S. National Library of Medicine.
© 2005-2016 VLP Biotech, Inc.